Records containing: Secondary Hyperparathyroidism Due to Renal Causes
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-09-03Quality of Life Change in Patients Undergoing Parathyroidectomy With Secondary Hyperparathyroidism Due toEnd-stage Renal Failure: a Retrospective Cohort Study
-
CLINICAL_TRIALS study record update · 2025-03-30A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis.
-
CLINICAL_TRIALS study record update · 2023-01-09A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation
-
CLINICAL_TRIALS study record update · 2022-12-09An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
-
CLINICAL_TRIALS study record update · 2020-02-13Changes of Pulmonary Function, Voice and Swallowing Symptoms After Total Parathyroidectomy for Secondary Hyperparathyroidism in the Presence of Intact Recurrent Laryngeal Nerve
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2018-11-19Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.